A patient-derived nude-mouse model of soft-tissue sarcoma has been established and treated in the following groups: (1) untreated controls; (2) gemcitabine (GEM) (80 mg/kg, ip, weekly, 3 weeks); (3) Pazopanib (100 mg/kg, orally, daily, 3 weeks) and (4) Salmonella typhimurium A1-R (5 × 10 7 CFU/body, ip, weekly, 3 weeks). The sarcoma was resistant to GEM (p = 0.879). Pazopanib tended to reduce the tumor volume compared to the untreated mice, but there was no significant difference (p = 0.115). S. typhimurium A1-R significantly inhibited tumor growth compared to the untreated mice (p = 0.001). S. typhimurium A1-R was the only effective treatment for the soft-tissue sarcoma nude mouse model among all treatments including a newly approved multiple tyrosine kinase inhibitor; Pazopanib. These results suggest tumor-targeting S. typhimurium A1-R is a promising treatment for chemoresistant soft-tissue sarcoma.
Introduction
Soft-tissue sarcomas are rare mesenchymal cancers comprising approximately 50 histological types [1] . The yearly incidence of soft-tissue sarcomas in the USA is 11,280 cases, with 3,900 deaths. Patients with metastatic soft-tissue sarcomas have a median overall survival of about 12 months.
Pazopanib (Votrient) is a multiple tyrosine kinase inhibitor approved for the treatment of advanced (unresectable and/or metastatic) soft-tissue sarcomas in patients who have received prior chemotherapy. Pazopanib improved progression-free survival in a Phase III clinical trial [2] .
An attenuated strain of Clostridium novyi (C. novyi-NT) was used to treat a human patient who had an advanced leiomyosarcoma. Treatment was intratumor (i.t.) injection of C. novyi-NT spores. C. novyi-NT regressed the tumor within and surrounding the bone [3] .
Our laboratory has previously developed a genetically-modified bacteria strain, Salmonella typhimurium A1-R, selected for tumor-targeting in vivo. S. typhimurium A1-R is auxotrophic for leu and arg [4] . The strain targets and grows in tumors. In contrast, normal tissue is cleared of these bacteria even in immunodeficient athymic mice. S. typhimurium A1-R is effective against prostate cancer [5] , breast cancer [6, 7] , pancreatic cancer [8] [9] [10] [11] , glioma [12, 13] , lung cancer [14] , fibrosarcoma [15] and osteosarcoma [16] .
In the present study, we report the efficacy of S. typhimurium A1-R against a human patient chemo-resistant sarcoma growing in nude mice. Tumors growing in nude mice can faithfully replicate important features of the patient's cancer, such as tumor markers even after passage [17, 18] .
Materials and Methods Animals
Male athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4-6 weeks old, were used in this study. Mice were kept in a barrier facility under HEPA filtration. Mice were fed with autoclaved laboratory rodent diet. All mouse surgical procedures and imaging were performed with the animals anesthetized by intramuscular injection of 50% ketamine, 38% xylazine, and 12% acepromazine maleate (0.02 ml solution). All animal studies were conducted with an AntiCancer Institutional Animal Care and Use Committee (IACUC)-protocol specifically approved for this study and in accordance with the principals and procedures outlined in the National Institute of Health Guide for the Care and Use of Animals under Assurance Number A3873-1.
Specimen collection
The patient provided informed written consent and samples were procured and the study was conducted under the approval of the Institutional Review Board of the UC San Diego Medical Center.
Establishment of patient nude mouse model of sarcoma
Tumor tissues were obtained from the patient with a metastatic soft-tissue sarcoma of the retroperitoneum at biopsy and cut into fragments (3-mm 3 ) and transplanted subcutaneously in nude mice. Tumors in the present study were in their second passage.
Preparation of bacteria
S. typhimurium A1-R was grown overnight on LB medium and then diluted 1:10 in LB medium. Bacteria were harvested at late-log phase, washed with PBS, and then diluted in PBS. Bacteria were then used for experiments [6] .
Treatment of soft-tissue sarcoma in nude mice
The patient sarcoma established in nude mice was passaged subcutaneously to 20 nude mice to determine the efficacy of various treatments. Four weeks after implantation, the mice in each model were randomized to 6 mice in the untreated control and 4 groups of 5 mice in each treatment group and treated as follows: (1) 
Tissue histology
Tumor samples were removed with surrounding normal tissues at the time of resection. Fresh tissue samples were fixed in 10% formalin and embedded in paraffin before sectioning and staining. Tissue sections (5 μm) were deparaffinized in xylene and rehydrated in an ethanol series. Hematoxylin and eosin (H & E) staining was performed according to standard protocols. The sections were examined using a BH-2 microscope (Olympus, Tokyo, Japan) equipped with a INFINITY1 2.0 megapixel CMOS digital camera (Lumenera Corporation, Ottawa, Canada). All images were acquired using INFINITY ANALYZE software (Lumenera Corporation) without post-acquisition processing.
Evaluation of histopathological response to treatment
Histopathological response to treatment was defined according to Evans's grading scheme: Grade I, little (<10%) or no cancer cell destruction is evident; Grade IIa, destruction of 10%-50% of cancer cells; Grade IIb, destruction of 51%-90% of cancer cells; Grade III, few (<10%) viable-appearing cancer cells are present; Grade IV, no viable cancer cells are present [11, 19] .
Confocal imaging of S. typhimurium A1-R-GFP in sarcoma tissue
Resected sarcoma specimens from mice treated with S. typhimurium A1-R were embedded with optimal cutting temperature (OCT) compound (Tissue-Tek; Sakura Finetek Europe BV, Zoeterwude, Netherlands) and preserved in liquid nitrogen. Frozen sections of 7-10 μm thickness were prepared with a CM1850 cryostat (Leica, Wetzlar, Germany). The frozen sections were directly observed with a confocal microscope (Fluoview FV1000, Olympus, Tokyo, Japan). Excitation sources were semiconductor lasers at 473 nm for GFP excitation. After confocal imaging, frozen sections were fixed in 10% formalin and H & E staining was performed.
Culture of GFP-labeled S. typhimurium A1-R bacteria from tumors and organs
Subcutaneous tumors and normal nude mouse organs (blood and liver) were removed at the termination of the treatment experiments. Bacteria were isolated from the tumors and organs and cultured in LB agar for 24 hours, and imaged with the OV100 small animal imaging system (Olympus, Tokyo, Japan) [20] .
Statistical analysis
PASW Statistics 18.0 (SPSS, Inc) was used for all statistical analyses. The Student's t-test was used to compare continuous variables between two groups. A p value of 0.05 was considered statistically significant for all comparisons.
Results and Discussion
Soft-tissue patient sarcoma grown in nude mice recapitulates the histology of the original tumor
The majority of the original-tumor section was comprised of sarcomatous high grade spindle cells of varying sizes, demonstrating abundant, finely granular cytoplasm and atypical, pleomorphic, round-to-elongated nuclei with irregular nuclear membranes, an open chromatin pattern and prominent nucleoli (Fig 1A) . The mouse-grown tumors had histological structures similar to the original tumor (Fig 1B) .
S. typhimurium A1-R is highly effective on the patient soft-tissue sarcoma in nude mice
The relative tumor volume on day 22, compared to day 1, of each group was as follows: (1) untreated control: 6.61 ± 2.37; (2) GEM: 6.39 ± 2.26; (3) Pazopanib: 3.94 ± 2.71; (4) S. typhimurium A1-R: 1.58 ± 0.37 (Fig 2) . The sarcoma did not significantly respond to GEM (p = 0.879). Pazopanib tended to reduce the tumor volume compared to the untreated mice, but there was not a significant difference (p = 0.115). S. typhimurium A1-R significantly inhibited the sarcoma tumor growth compared to the untreated control mice (Fig 2) (p = 0.001).
Sizes of all tumors are listed in the S1 Table. No body weight loss was found in any treatment groups.
Histological response to treatment
Histopathological response to each treatment was defined according to Evans's grading scheme. In the control (no treatment) and GEM-treated sections, the tissue sections from the tumor were occupied by viable cancer cells (Fig 3A and 3B) . Approximately 40% of cancer cells were destroyed and replaced by stromal cells in the tumor sections treated with Pazopanib ( Fig  3E) . Tumors treated with S. typhimurium A1-R consisted of 2 components; one was a viablelike component and the other one was a necrotic component. The viable-like component was occupied by cancer cells (Fig 3D) . In contrast, no viable cancer cell were detected in a necrotic component of the S. typhimurium A1-R-treated tumor (Fig 3E) . Although the viable cancer cells were found, they did not form a tumor as can be seen from Fig 2. The untreated control and GEM were judged as grade I; Pazopanib as IIa; S. typhimurium A1-R of a viable-like component as grade I and the necrotic component as IV. The necrotic component was not detected in any treatment group except for S. typhimurium A1-R (Fig 3A-3E) . Tumor heterogeneity may be a factor in the observed chemoresistance of the soft tissue sarcoma that was overcome by S. typhimurium A1-R. GFP-labeled S. typhimurium A1-R was isolated from the tumor (Fig 4) , but not from blood and only minimally from liver, indicating the tumor was effectively targeted by S. typhimurium A1-R.
S. typhimurium A1-R was the only effective treatment for the soft-tissue patient sarcoma growing in nude mice including GEM and a newly approved multiple tyrosine kinase inhibitor; Pazopanib. One factor in chemoresistance of solid tumors is that the majority of the cancer cells within the tumor are in a chemoresistant G 0 /G 1 quiescent cell-cycle phase [21] . We have recently shown that quiescent cancer cells are sensitive to S. typhimurium A1-R [22] . S. typhimurium A1-R, unlike C. novyi-NT, is a facultative anaerobe and can be administered systemically such as in the present study (i.p.), whereas C. novyi-NT seems to require i.t. administration which makes it different to target metastasis. The results of the present study indicate tumor-targeting S. typhimurium A1-R is a promising treatment for soft-tissue sarcomas. In future experiments, S. typhimurium A1-R will be tested in a series of patient soft tissue sarcoma grown in mice as a bridge to the clinic, where we also intend to focus on sarcoma. Evaluation of biomarker expansion under various treatment regimens will be evaluated in future experiments.
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